Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study

BACKGROUND: The combination of umeclidinium (UMEC), a long-acting muscarinic receptor antagonist, and vilanterol (VI), a selective long-acting β(2) agonist, is in development for the treatment of chronic obstructive pulmonary disease (COPD). This study evaluated the pharmacokinetics, safety and tole...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Rashmi, Kelleher, Dennis, Preece, Andrew, Hughes, Stephen, Crater, Glenn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615930/
https://www.ncbi.nlm.nih.gov/pubmed/23569370
http://dx.doi.org/10.2147/COPD.S40859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615930/
https://www.ncbi.nlm.nih.gov/pubmed/23569370
http://dx.doi.org/10.2147/COPD.S40859

Ejemplares similares